Online citations, reference lists, and bibliographies.
← Back to Search

Eleven Years Of Inflexal V-a Virosomal Adjuvanted Influenza Vaccine.

C. Herzog, K. Hartmann, Valérie Künzi, O. Kürsteiner, R. Mischler, H. Lazar, R. Glueck
Published 2009 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal V have been completed in which 3920 subjects participated. During its decade on the market, Inflexal V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal V during the past decade.
This paper references
10.1186/1471-2334-7-141
Influenza activity in Europe during eight seasons (1999–2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe
J. Paget (2007)
10.1016/J.VACCINE.2006.05.084
Inflexal V--the influenza vaccine with the lowest ovalbumin content.
O. Kürsteiner (2006)
10.1016/S0264-410X(99)00404-1
Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes.
A. Arkema (2000)
10.1177/147323000403200506
Immunogenicity and Tolerability of a Trivalent Virosomal Influenza Vaccine in a Cohort of HIV-Infected Children
G. Zuccotti (2004)
10.1038/nature06945
The genomic and epidemiological dynamics of human influenza A virus
A. Rambaut (2008)
Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system.
S. Cryz (1998)
10.1038/nrd1176
Recent advances in the discovery and delivery of vaccine adjuvants
D. O'hagan (2003)
10.1016/S1045-1870(98)80059-9
Influenza virus infections in children
M. Brady (1998)
10.2165/00003495-200262070-00003
Pharmacoeconomics of Influenza Vaccination for Healthy Working Adults
M. Postma (2012)
10.1016/J.VACCINE.2006.05.034
Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.
L. Salleras (2006)
10.1016/J.VACCINE.2007.07.027
Influenza vaccine: the challenge of antigenic drift.
F. Carrat (2007)
10.3201/eid1201.051254
Influenza Pandemics of the 20th Century
E. Kilbourne (2006)
10.1056/NEJM200001273420401
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.
K. Neuzil (2000)
10.1038/nature04239
Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution
E. Ghedin (2005)
10.1016/S0264-410X(96)00040-0
A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans.
S. Cryz (1996)
10.1056/NEJM200103223441204
The Japanese experience with vaccinating schoolchildren against influenza.
T. A. Reichert (2001)
[Vaccination against influenza in the elderly. Experience with adjuvant vaccines].
V. Baldo (1999)
10.1056/NEJM200001273420402
Influenza and the rates of hospitalization for respiratory disease among infants and young children.
H. Izurieta (2000)
Influenza vaccination ofHIV1positive andHIV1negative former intravenous drug users
GB Gaeta (2001)
10.4161/hv.3.1.3657
Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age
M. Marchetti (2007)
Comparison of the safety and immunogenicity of 2 adjuvanted influenza vaccines in elderly subjects
M Zamparo (1997)
10.4161/hv.2.1.2494
Applications of Influenza Virosomes as a Delivery System
M. G. Cusi (2006)
10.1056/NEJM199805143382002
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
R. Belshe (1998)
10.1016/S0264-410X(03)00070-7
The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines.
K. Nichol (2003)
10.1097/QAI.0b013e3181632cda
Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy
A. Viganò (2008)
10.1016/S0264-410X(02)00510-8
Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis.
G. Gaeta (2002)
10.1016/J.VACCINE.2005.04.026
The virosome concept for influenza vaccines.
A. Huckriede (2005)
10.1126/science.1154137
The Global Circulation of Seasonal Influenza A (H3N2) Viruses
C. Russell (2008)
10.1016/j.vaccine.2008.06.095
Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy.
S. Esposito (2008)
10.1016/j.vaccine.2008.12.008
Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Valérie Künzi (2009)
10.1007/BF03351492
Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly
F. Pregliasco (2001)
erability and efficacy of antiinfluenza vaccination alone and associated with antipneumococcal vaccination in an elderly ambulatory population and adherence to the vaccination campaign
S Consonni (2004)
10.1016/J.VACCINE.2005.04.020
Clinical experience with inactivated, virosomal influenza vaccine.
I. D. de Bruijn (2005)
10.1016/J.VIRUSRES.2004.02.026
Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.
I. D. de Bruijn (2004)
10.1016/S0264-410X(02)00103-2
Virosome-mediated delivery of protein antigens to dendritic cells.
L. Bungener (2002)
10.1586/14760584.6.5.711
Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations
C. Moser (2007)
10.1016/S0264-410X(02)00508-X
Virosome influenza vaccine in children.
C. Herzog (2002)
10.1016/J.VACCINE.2005.08.054
Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years.
S. Esposito (2006)
10.1002/JMV.20559
Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T‐cell activation in HIV‐infected children receiving highly active antiretroviral therapy
E. Tanzi (2006)
10.1111/j.1651-2227.2002.tb01676.x
Immunogenicity and safety of a virosomal influenza vaccine in HIV‐infected children
G. V. Zuccotti (2002)
10.2741/1452
Current vaccine adjuvants: an overview of a diverse class.
C. Kensil (2004)
10.1016/J.VACCINE.2004.08.044
Population-wide benefits of routine vaccination of children against influenza.
D. Weycker (2005)
10.1097/00006454-200404000-00005
Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children
G. Kanra (2004)
10.1128/AAC.44.5.1163-1167.2000
Comparison of Immunogenicity and Safety of a Virosome Influenza Vaccine with Those of a Subunit Influenza Vaccine in Pediatric Patients with Cystic Fibrosis
U. Schaad (2000)
Effec - tiveness of virosomal subunit influenza vaccine in preventing influenzarelated illnesses and its social and economic consequences in children aged 3 – 14 years : a prospective cohort study
E Navas (2006)
10.1542/peds.2004-1519
Adverse Events After Inactivated Influenza Vaccination Among Children Less Than 2 Years of Age: Analysis of Reports From the Vaccine Adverse Event Reporting System, 1990–2003
A. W. McMahon (2005)
10.1056/NEJMP038238
Influenza vaccine--outmaneuvering antigenic shift and drift.
J. Treanor (2004)
10.2165/00128415-200912470-00068
Influenza vaccines
Carol A. McCarthy (1965)
10.1016/J.VACCINE.2004.06.036
Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.
S. A. Frech (2005)
10.1006/VIRO.2002.1491
Influenza A virus specific T cell immunity in humans during aging.
A. Boon (2002)
10.2165/00063030-199911020-00007
Liposomal Influenza Vaccine
Kristin J. Holm (2012)
10.1542/peds.2008-2449
Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2008–2009
J. Bocchini (2008)
10.1016/J.VACCINE.2006.09.042
Influenza vaccination: the paediatric perspective.
J. Ramet (2007)
10.1038/nchembio.77
Progressive ordering with decreasing temperature of the phospholipids of influenza virus.
I. V. Polozov (2008)
10.1016/J.VACCINE.2007.07.013
Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
G. Zuccotti (2007)
Adjuvanted virosomal vaccine vs conventional vaccine for the control of influenza in the elderly. An Economic evaluation
R. Gasparini (2001)
10.1016/S0264-410X(01)00060-3
Comparison of three different influenza vaccines in institutionalised elderly.
V. Baldo (2001)
Humoral and cell-mediated immune response to a virosomal influenza vaccine in healthy elderly
C. Mensi (2001)
10.1016/j.febslet.2006.04.084
Post‐genomic vaccine development
D. Serruto (2006)
10.1016/S0264-410X(97)00087-X
Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients.
P. Conne (1997)
10.1016/S0140-6736(94)92758-8
Immunogenicity of new virosome influenza vaccine in elderly people
R. Glück (1994)
10.1016/S0952-7915(00)00120-5
Immunological concepts of vaccine adjuvant activity.
V. Schijns (2000)
10.1016/J.VACCINE.2007.01.038
Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
E. Navas (2007)
10.1016/j.vaccine.2005.07.046
A review of vaccine research and development: Human acute respiratory infections☆
M. Girard (2005)
10.1016/S0264-410X(03)00071-9
The annual production cycle for influenza vaccine.
C. Gerdil (2003)
Protective efficacy of Inflexal V in elderly
F. Pregliasco (2002)
10.1056/NEJMOA020546
Influenza-related hospitalizations among children in Hong Kong.
S. Chiu (2002)
10.1016/S0264-410X(02)00512-1
Inflexal V a trivalent virosome subunit influenza vaccine: production.
R. Mischler (2002)
10.1002/JMV.2085
Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users
A. Amendola (2001)
10.1097/00019048-200203000-00014
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
C. Bridges (2002)
10.1016/S0149-2918(02)85008-1
An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.
B. de (2002)
/ Vac of age : analysis of reports from the vaccine adverse event reporting system , 1990 – 2003
V Künzi (2005)
10.1007/s15010-004-3204-z
Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly
B. Ruf (2004)
10.1016/S0264-410X(02)00511-X
Safety and immunogenicity of influenza vaccination in individuals infected with HIV.
A. Zanetti (2002)
10.1128/JVI.48.1.52-60.1983
Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites.
G. Both (1983)



This paper is referenced by
New strategies for simplifying influenza vaccination
W. L. Hinrichs (2014)
10.1002/biot.201600579
Microscale disruption of microorganisms for parallelized process development
C. Walther (2017)
10.1586/erv.11.189
Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants
C. Olive (2012)
10.1016/j.antiviral.2012.07.003
Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
Masoumeh Tavassoti Kheiri (2012)
10.3389/fmicb.2018.00123
Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture
D. Rajão (2018)
10.4018/978-1-4666-6363-3.CH014
Liposome-Encapsulated Antimicrobial Peptides: Potential Infectious Diseases Therapy
A. Gupta (2015)
10.3390/pharmaceutics11030124
What Drives Innovation: The Canadian Touch on Liposomal Therapeutics
Ada W. Y. Leung (2019)
10.1016/j.vaccine.2016.04.089
Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
Alina Venereo-Sánchez (2016)
10.1021/acs.chemrev.5b00116
Clinical Translation of Nanomedicine.
Y. Min (2015)
10.1007/s00430-013-0313-2
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing
H. Liu (2013)
10.1016/B978-0-323-35761-6.00031-6
31 – Inactivated Influenza Vaccines
J. Bresee (2018)
10.1016/j.cis.2019.07.006
The Why, Where, Who, How, and What of the vesicular delivery systems.
B. Kapoor (2019)
10.1016/j.coph.2018.03.014
Adjuvant strategies to improve vaccination of the elderly population
B. Weinberger (2018)
Modification to the immunodominant loop of hepatitis B virus core protein to enhance vector properties of virus-like particles
Justin Hean (2014)
10.5772/48513
Dendritic Cells Interactions with the Immune System – Implications for Vaccine Development
Aiala Salvador (2012)
10.1016/j.vaccine.2018.09.021
Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan.
Haruka Momose (2018)
10.1016/j.ejmech.2019.01.007
Composition design and medical application of liposomes.
Mingyuan Li (2019)
10.1039/C5RA22258C
Efficient Passerini reactions in an aqueous vesicle system
Daniel Paprocki (2015)
10.1016/S1576-9887(10)70030-3
Vacunación frente a la gripe por vía intradérmica
José Ramón de Juanes Pardo (2010)
10.1016/J.AJPS.2013.07.010
Development of liposomal formulations: From concept to clinical investigations
Yuchen Fan (2013)
10.2217/nnm.14.193
The impact of size on particulate vaccine adjuvants.
Ruchi R Shah (2014)
Préparation à petite et grande échelle des liposomes encapsulant l’huile essentielle de clou de girofle libre et sous forme de complexe d’inclusion dans l’hydroxypropyl-β-cyclodextrine : caractérisation des nanostructures et évaluation de leur effet antioxydant
Carine Sebaaly (2016)
10.4161/hv.23239
Cross-protection against drifted influenza viruses
A. Orsi (2013)
Features of the Patent Researches of Nanotechnology-Based Drug Development
O. Posylkina (2016)
10.2217/AHE.10.17
Influenza viral infection in the elderly
David R. P. Guay (2010)
10.4155/CLI.13.19
Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials
Leonoor Wijnans (2013)
10.2174/1875035401003010108
Safety of a Virosomal Adjuvanted Influenza Vaccine in Children Suffering from Chronic Disease
Gian Vincenzo Zuccotti (2010)
10.2165/11586770-000000000-00000
Inactivated Influenza Vaccines
Valentina Parodi (2011)
10.1016/j.vaccine.2012.10.083
Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development
N. Kushnir (2012)
10.1016/S1576-9887(09)73476-4
Low reactogenicity of the virosomal subunit influenza vaccine in healthy children without risk factors
Lluís Salleras (2009)
10.1111/cei.13287
Novel approaches for the design, delivery and administration of vaccine technologies
J. Wallis (2019)
10.1007/978-3-319-25832-4
Introduction to Molecular Vaccinology
Matthias Giese (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar